InvestMoat
Healthcare | PharmaceuticalsGLP-1 Dominant

Eli Lilly and Company

LLY~$1.09T capAnalysed Oct 30

Hold

Hold for Long-Term Compounding

73
Moat71
Growth81
Val66
0255075100

Combined average of Moat (AI Resilience), Growth, and Valuation scores.

71/100

Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.

Eli Lilly's moat is anchored in scientific superiority and regulatory exclusivity that cannot be replicated quickly:

  • Tirzepatide Efficacy Superiority: Mounjaro and Zepbound (tirzepatide) consistently outperform competing GLP-1 drugs in head-to-head efficacy data, with superior weight loss outcomes. This clinical evidence edge drives prescriber preference and formulary positioning that competitors must overcome with their own Phase 3 trial data — a multi-year barrier.
  • Patent Wall Into the Late 2030s: Lilly's CEO has confirmed tirzepatide compound patent protection extends 'into the back half of the 2030s' in major markets, contrasting sharply with Novo Nordisk's semaglutide facing patent expiry in select markets today. This 10+ year runway allows Lilly to compound its GLP-1 franchise revenues without near-term generic erosion.
  • Manufacturing Moat at Scale: Peptide manufacturing is extraordinarily complex; Lilly has invested billions into new manufacturing capacity globally. The expertise required to manufacture GLP-1 drugs at commercial scale — including sterile fill-finish and cold-chain logistics — represents a structural barrier that takes years for competitors to build.

Lilly's core moat — patent-protected biologics with regulatory approval — is structurally immune to AI disruption, and AI drug discovery tools actually accelerate Lilly's pipeline advantage by compressing early-stage discovery timelines. The company is a net beneficiary of AI adoption, using it to identify novel targets and optimize clinical trials faster than underfunded competitors.

72.0 resilient · 65.0 vulnerable · 80/20 = 70.6 · = 71

Open a moat to read its note.

AI-Vulnerable Moats2 intact · 3 N/A
AI-Resilient Moats1 strong · 4 intact · 2 N/A

Lilly's moats hold through the decade. Tirzepatide compound patents run into the back half of the 2030s, so the approvals, formulary placement and trial data stay protected for the whole horizon, and the manufacturing build-out keeps Lilly the largest incretin producer. Generic semaglutide in some markets and oral small-molecule GLP-1s from other makers will make the category more price-competitive, but neither has yet taken tirzepatide share, so no pillar is called in either direction.

No moat trending · 71 holds

Compare side by side

Is Eli Lilly and stock a buy?

We rate Eli Lilly and Hold, with a composite score of 73/100: moat 71, growth 81 and valuation 66. The valuation score is struck against our bear, base and bull targets and moves with the price.

What is Eli Lilly and's moat?

Eli Lilly and scores 71/100 on moat. Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.

How fast is Eli Lilly and expected to grow?

We estimate 15-22% a year over the next three to five years, for a growth score of 81/100.

What is Eli Lilly and's price target?

Our base case is $1,400, with $850 in the bear case and $2,100 in the bull case.